Bavituximab just may become the #1 combination treatment for Alzheimers. The story is slowly reaching the right places and I hope Peregrine releases some information soon to show the medical community what possibilities exist for oncology, HIV and hundreds of other auto-immune diseases.
Do I still believe in PS Targeting becoming the #1 combination treatment ...? Yes
For Alzheimers ? Yes... yes and yes.
Why is it taking a little bit longer? Well first was the sabotage attempts and now I believe we just need to make sure manufacturing can be handled for global demand and all the while... the continuition of building, gathering and collecting research data that all points to PS Targeting being as as big as the late Dr. Philip Thorpe thought it would become and it continues daily... next with Biogen!
------------------------------
As Biogen Prepares to Reveal Alzheimer's Data, Expectations Are High
by: Adam Feuerstein
March 16, 2015
CAMBRIDGE, Mass. (TheStreet) -- Researchers on behalf of Biogen Idec (BIIB - Get Report) on Friday will present detailed results for the first time from an early-stage study of the company's experimental drug BIIB037 in patients with the mildest forms of Alzheimer's disease.
Friday's presentation is important because it will fill in key details about BIIB037 that were left unanswered last December, when Biogen first told investors the drug demonstrated a statistically significant reduction in amyloid levels and improved cognition compared to a placebo.
The successful phase I study was small, and Biogen still must conduct larger phase III studies to confirm the positive effect of BIIB037 on Alzheimer's patients. (The company announced in December that it was "fast tracking" the drug, and skipping the phase II study.) But Biogen has added $25 billion in market value since the December announcement -- a sign investors are willing to believe BIIB037 might succeed where several other similar Alzheimer's drugs have failed.
Amyloid beta (Aß or Abeta) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of the amyloid plaques found in the brains of Alzheimer patients.
Formation of amyloid fibers triggered by phosphatidylserine-containing membranes.
Zhao H 1, Tuominen EK, Kinnunen PK. Author information
1Helsinki Biophysics and Biomembrane Group, Institute of Biomedicine, P.O. Box 63 (Haartmaninkatu 8), University of Helsinki, FIN-00014 Helsinki, Finland.
Abstract
Protein misfolding has been shown to be the direct cause of a number of highly devastating diseases such as Alzheimer's disease, Parkinson's disease, and Creutzfeldt-Jacob syndrome, affecting the aging population globally. The deposition in tissues of amyloid fibrils is a characteristic of all these diseases, and the mechanisms by which these protein aggregates form continue to be intensively investigated. In only a fraction of cases is an underlying mutation responsible, and accordingly, what initiates amyloid formation in vivo is the major question that is addressed. In this study, we show that membranes containing phosphatidylserine (PS), a negatively charged phospholipid, induce a rapid formation of fibers by a variety of proteins, viz., lysozyme, insulin, glyceraldehyde-3-phosphate dehydrogenase, myoglobin, transthyretin, cytochrome c, histone H1, and alpha-lactalbumin. Congo red staining of these fibers yields the characteristic light green birefringence of amyloid, and fluorescent lipid tracers further reveal them to include phospholipids. Our results suggest that PS as well as other acidic phospholipids could provide the physiological low-pH environment on cellular membranes, enhancing protein fibril formation in vivo. Interestingly, all the proteins mentioned above either are cytotoxic or induce apoptosis. PS-protein interaction could be involved in the mechanism of cytotoxicity of the aggregated protein fibrils, perturbing membrane functions. Importantly, our results suggest that this process induced by acidic phospholipids may provide an unprecedented and generic connection between three current major areas of research: (i) mechanism(s) triggering amyloid formation, (ii) cytotoxicity of amyloidal protein aggregates, and (iii) mechanism(s) of action of cytotoxic proteins.
Read, re-read and re-read again the above. Every time I was going to highlight in red one section... its obvious the entire paragraph is important and guess what else is important???
PS Targeting
PS Targeting
PS Targeting
and no, targeting TIM1 TIM2 TIM3 or AXL..etc..etc all by itself is not sufficient and does not cover the entire spectrum as PS Targeting does.
Damn, I hope every in debt to school tuition researcher, Phd, Scientists ..etc..etc..etc will be part of the long rise of PPHM to come. Its one thing to have II and big Funds who can not buy till we pass $5 to lock in their shares and then have the agenda to move us higher but has any biotech stock ever had the foundation as PS Targeting ? No way
...and with every collaboration big and small, Universities public and private down to the admin assistant that is soon to be well aware of how valuable PS Targeting will be can become shareholders in this very big bright future.
There will become dozens and dozens of peer reviewed publications all telling about what many here have known for a long time, especially since the sabotage of Peregrine Pharmaceuticals.
-------------------------------------------------
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
